News
02.02.2026
PhD Candidate Zoe Marti, Cellerys, successfully defended her thesis February 2, 2026.
The 2026 FAN Awardees are shown together with Vice President for Research of the University of Zurich, Prof. Elisabeth Stark. Left to right: Zoe Martin (PhD candidate and award of the Faculties of Medicine and Mathematics and Natural Sciences), Prof. Stark, Stephanie Santschi (post-doc; award of the Department of Art History), and Stefano Statunato (Doctoral candidate, award of the Faculty of Law)
February 3, 2026, she received the highly competitive FAN (Förderung des akademischen Nachwuchs; Promotion of young academic career researchers) Award of the University of Zurich Graduate Campus for her work on Epstein-Barr virus-specific T cell responses in multiple sclerosis.
23.12.2025
We are proud to report that the last patient in the Phase Ib RED4MS completed the last visit!
Claudia Mitchell (Chair): “This is an important milestone for the company and great achievement for the whole team. We are eagerly looking forward to see the full analysis of the data and to prepare for the next phase of clinical development”
Roland Martin (CSO): “Our research aims at an important unmet medical need in MS. Successful implementation of therapeutic immune tolerance will be a major breakthrough in treating autoimmune disease and in medicine.”
Andreas Lutterotti (CMO): “This is a very important achievement, and we are deeply grateful to all persons with MS participating in this first-in-human trial, all investigators and collaborators for their outstanding support.”
14.06.2024
Cellerys AG announces start of immune tolerance trial RED4MS trial in multiple sclerosis! We are pleased to announce that we are now screening the first patients for inclusion in our RED4MS phase IB/IIA clinical study. This important trial will be conducted in 4 countries across Europe and aims to demonstrate the power of immune tolerizing approaches for patients with multiple sclerosis.
Study Details | Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis | ClinicalTrials.gov
In the Press
12.04.2023
National Multiple Sclerosis Society
Noted MS Neurologist Dr. Roland Martin Wins 2023 John Dystel Prize for Multiple Sclerosis Research.
Ganzen Artikel lesen
04.06.2021
Handelszeitung
Warum Novartis beim Zürcher Startup Cellerys einsteigt.
Ein Spin-Off des Unispitals Zürich könnte den Kampf gegen Multiple Sklerose und andere Erkrankungen revolutionieren. Nun greift Novartis zu. Ganzen Artikel lesen ↓ Download PDF
13.12.2021
SRF Puls: Klinische Studien – Der lange Weg zu neuen Medikamenten
Normalerweise dauert es viele Jahre, bis ein neues Medikament, eine neue Therapie zugelassen wird – wenn überhaupt. Die Hürden sind hoch, und es braucht Freiwillige für die ersten Tests an Menschen. «Puls» hat bei der Entwicklung eins neuen Medikaments hinter die Kulissen geblickt.
Link zum Beitrag auf SRF